Genmab — Juli 2013
-
...jeg er mindre end imponeret
-
-
gentogen - postede du ikke et link til en større rapport, der bla omhandlede resultater på fase IV?
-
det er blot 1-2 uger siden
-
jeg mener bestemt, at det var pfs. Det stod vistnok på side 54, men nu kan jeg ikke genfinde rapporten
-
Du har ret sukker - Summary / Conclusion:These results show that with the only exception of the ORR
(lower in this study) all endpoints (PFS, OS) and safety profile in CLL patients treated with ofatumumab in daily practice are consistent with those observed in phase II
and III clinical trials. -
står på side 47 i denne rapport: http://www.haematologica.org/content/98/supplement_1/1.full.pdf
-
orr er 23%
-
jep - godkendelsen var baseret på ORR=42% - http://www.hematology.org/News/2009/4384.aspx
-
-
http://finance.yahoo.com/q?s=GNMSF 50.000 stk
omsat -
Også lidt her (dog ikke ny): Se under David Satijn ved at scrolle ned: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502230/
-
tak for den Gen - du er en ørn til at finde info omkring GEN!
-
Intas launches Mabtas, a biosimilar version of Rituximab May 02, 2013
Intas Pharmaceuticals Ltd. has launched Mabtas, a biosimilar version of Rituximab competent in
treating diseases characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B
cells like Chronic Lymphocytic Leukaemia (CLL) and Rheumatoid Arthritis apart from Non-Hodgkin's
Lymphoma (NHL) in India. With a view to make NHL treatment cost-effective, Mabtas is manufactured
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind